Repurposing of Zika virus live-attenuated vaccine (ZIKV-LAV) strains as oncolytic viruses targeting human glioblastoma multiforme cells.

ABSTRACT: Glioblastoma multiforme (GBM) is the most common malignant primary brain cancer affecting the adult population. Median overall survival for GBM patients is poor (15 months), primarily due to high rates of tumour recurrence and the paucity of treatment options. Oncolytic virotherapy is a promising treatment alternative for GBM patients, where engineered viruses selectively infect and eradicate cancer cells by inducing cell lysis and eliciting robust anti-tumour immune response. In this study, we evaluated the oncolytic potency of live-attenuated vaccine strains of Zika virus (ZIKV-LAV) against human GBM cells in vitro. Our findings revealed that Axl and integrin α_vβ₅ function as cellular receptors mediating ZIKV-LAV infection in GBM cells. ZIKV-LAV strains productively

SUBMITTER: Victorio CBL 

PROVIDER: S-EPMC10835997 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature